Cellares and TScan to assess automated manufacturing of TSC-101 therapy

Pharmaceutical Technology

Cellares and TScan Therapeutics have entered a deal to assess automated manufacturing for TScan's TSC-101 therapy in AML and MDS patients.

pharminent June 4, 2026 (Last updated: June 4, 2026)

Pharmaceutical Technology

Cellares and TScan Therapeutics have entered a deal to assess automated manufacturing for TScan’s TSC-101 therapy in AML and MDS patients.

Related Stories